Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCS-21 in Healthy Volunteers
NCT06752122Phase 1Recruiting
- Sponsor
- RNATICS
- Start
- Feb 2025
- Primary completion
- Jan 2027
- Modality
- RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RCS-21 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by RNATICS. Primary endpoint: Adverse Events at 6 months. Started Feb 2025; status: recruiting.
02
Drugs
RCS-21
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06752122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06752122.